The Swiss firm behind a possible Ebola vaccine
An Ebola vaccine undergoing clinical trials in Lausanne was first developed by an Italian with venture capital from Basel. (SRF/swissinfo.ch)
Clinical testing in humans for the vaccine is taking place at the Lausanne University Hospital. The vaccine was chosen for the trials by the World Health Organisation and is produced by the British company GlaxoSmithKline. It was first developed by a small biotech company based in Basel, before being sold for the sum of €250 million (CHF301 million).
The firm, Okairos, was headed by Riccardo Cortese, an Italian molecular biologist, who devised the technologies behind the Ebola vaccine in his laboratories. He works near Rome where he directs his own research laboratories but still lives in Basel.
The technology used by GlaxoSmithKline for the Ebola vaccine will also be used to develop vaccines against hepatitis C, HIV and malaria.
More
Swiss reject plans for bigger motorways and extra rights for landlords
More
Why cars still reign supreme in ‘rail-nation’ Switzerland
More
Taxes on pension payments: no problem for the Swiss Abroad
More
Azeri fossil-fuel cash cow brings controversy to Switzerland
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.